Decision Letter: Request for 2018 Renewal of Gavi support for Inactivated Polio Vaccine

Your Excellency,

I am writing in relation to Moldova’s request for renewal of the New Vaccine Support (NVS) for Inactivated Polio Vaccine that was reviewed by the Gavi Secretariat on 25 October 2017.

Following the recommendations made by the Gavi Secretariat review, I am pleased to inform you that Gavi has approved Moldova’s request to renew Gavi support for Inactivated Polio Vaccine for 2018, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Moldova Support for Inactivated Polio Vaccine (IPV)
Appendix B: Moldova Support for Injection Safety Devices

Please do not hesitate to contact my colleague Ms Jamila Sherova, Senior Country Manager for Moldova, at jsherova@gavi.org if you have any questions or concerns.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
    The EPI Manager
    WHO Country Representative
    UNICEF Country Representative
    Regional Working Group
    WHO HQ
    UNICEF Programme Division
    UNICEF Supply Division
Decision Letter
Moldova - Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Moldova
2. Grant number: 1518-MDA-25d-X/15-MDA-08h-Y
3. Date of Decision Letter: 13/12/2017
4. Date of the Partnership Framework Agreement: 05/02/2015
5. Programme title: New Vaccine Support, Inactivated Polio Vaccine, routine
6. Vaccine type: Inactivated Polio Vaccine (IPV)
7. Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 1 dose per vial, LIQUID
8. Programme duration: 2015 - 2018
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th></th>
<th>2015-2017</th>
<th>2018</th>
<th>Total3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Programme (US$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015-2017</td>
<td>4,541</td>
<td>127,500</td>
<td>132,041</td>
</tr>
</tbody>
</table>
10. Vaccine introduction grant / Product switch grant: US$100’000 disbursed on 18th March 2015.
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)5

<table>
<thead>
<tr>
<th>Number of vaccines to be purchased with Gavi funds</th>
<th>2015-2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV Routine Programme (doses)</td>
<td></td>
<td>43,400</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td></td>
<td>4,541</td>
</tr>
<tr>
<td></td>
<td></td>
<td>127,500</td>
</tr>
</tbody>
</table>
12. Procurement agency: UNICEF.
13. Self-procurement: Not applicable.
14. Co-financing obligations: Not applicable
   Gavi’s usual co-financing requirements do not apply to IPV. However, Moldova is encouraged to contribute to vaccine and/or supply costs for IPV.
15. Operational support for catch-up campaigns: Not applicable
16. Additional reporting requirements:
   Reports and other information |Due dates |
   To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | 15 May |

1 Please refer to section 18 for additional information on IPV presentation.
2 This is the entire duration of the Programme.
3 This is the total amount endorsed by Gavi for 2015 to 2018.
4 This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
5 This is the amount that Gavi has approved.
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. To be agreed with Secretariat

17. Financial clarifications: Not applicable.

18. Other conditions: Not applicable.

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Moldova envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Moldova.

Signed by

Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017
Decision Letter
Moldova - Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Moldova
2. **Grant number:** 17-MDA-32a-X; 18-MDA-32a-X
3. **Date of Decision Letter:** 13/12/2017
4. **Date of the Partnership Framework Agreement:** 05/02/2015
5. **Programme title:** Injection safety devices
6. **Programme duration:** 2017-2018
7. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2017</th>
<th>2018</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3,500</td>
<td>2,000</td>
<td>5,500</td>
</tr>
</tbody>
</table>

8. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>TOTAL injection safety devices to be purchased with Gavi funds in each year</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AD syringes</td>
<td></td>
<td>33,000</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td></td>
<td>375</td>
</tr>
<tr>
<td>Annual Amounts for injection safety devices for all Gavi vaccines (US$)</td>
<td>3,500</td>
<td>2,000</td>
</tr>
</tbody>
</table>

Injection safety devices to be purchased with Gavi funds in each year, by type of support

<table>
<thead>
<tr>
<th>New Vaccine Support (NVS), HPV Quadrivalent, 1 dose per vial, LIQUID, Demonstration</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AD syringes</td>
<td>33,000</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>375</td>
</tr>
<tr>
<td>Annual Amounts for injection safety devices for Vaccine (US$)</td>
<td>2,000</td>
</tr>
</tbody>
</table>

9. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
10. **Self-procurement:** Not applicable.
11. **Co-financing obligations:** Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017

---

6 This does not include vaccines.
7 This is the entire duration of the Programme.
8 This is the total amount endorsed by Gavi for the entire duration of the Programme.
9 This is the amount that Gavi has approved.